In this issue:
Trastuzumab deruxtecan vs. trastuzumab emtansine in HER2+ metastatic breast cancer
Impact of inter-cycle treatment delays on mortality in early-stage breast cancer
Cognition and returning to work after breast cancer
Adjuvant trastuzumab for 9 weeks vs. 1 year for HER+ breast cancer
Complete axillary lymph node dissection: identifying indication for adjuvant CDK4/6 inhibitor
Capivasertib and fulvestrant for hormone receptor+, HER2– advanced breast cancer
Sequential antibody-drug conjugates in HER2-low metastatic breast cancer
7-gene biosignature for guiding RT in ductal carcinoma in situ following breast-conserving surgery
Trastuzumab deruxtecan in HER2-low advanced breast cancer with brain metastases
Postbiotic for abemaciclib-induced diarrhoea
Please login below to download this issue (PDF)